ACOR - Centrexion Therapeutics Begins U.S. IPO Effort
Quick Take
Centrexion Therapeutics (CNTX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing medication for moderate to severe chronic pain.
CNTX is in Phase 3 trials for three programs for its lead candidate. The firm has had promising results so far but faces a challenging and expensive road ahead.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Boston, Massachusetts-based Centrexion was founded in 2013 to develop therapeutics designed to overcome the